Eisai Alzheimer's Drug Discovery Foundation, Pharma Firms Form Biobank Alliance Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies. PGDx, Eisai to Develop Next-Generation Sequencing Biomarker Assay The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples. AmoyDx, Eisai Form CDx Development Alliance Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer. Bristol-Myers Squibb, H3 Biomedicine Form Cancer Immunotherapy Alliance H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing. Cancer Genetics Signs Biomarker Services Deal with H3 Biomedicine Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate. Feb 16, 2016 Eisai, Sysmex to Develop Dx, CDx for Dementia Dec 17, 2014 Oncodesign, Eisai Reach Deal to Assess Eribulin Apr 3, 2014 Eisai Researchers Developing microRNA-based Diagnostic for Alzheimer's Disease Premium Jul 11, 2013 Seegene and Eisai's Eidia Partner on MDx Tests in Japan Premium Jul 1, 2013 Seegene Signs Japan Marketing Deal with Eidia Jan 10, 2013 Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate Premium Jan 7, 2013 Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment Oct 10, 2012 Eisai to Dissolve Dx R&D Subsidiary as It Focuses on Personalized Medicine Oct 9, 2012 Foundation Medicine, Eisai Ink Personalized Med Alliance May 16, 2012 With Celgene Partnership Epizyme Hopes to Accelerate Personalized Epigenetic Drug Development Premium Apr 6, 2012 IP Update: Recent Patents Awarded to Thermo Fisher Scientific; Eisai; and More Premium Jul 1, 2011 Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche Premium May 4, 2011 Supreme Court Case on Script Data Sale Presents 'Gray Area' for PBM Personalized Rx Efforts Premium Apr 6, 2011 AACR Presentations Highlight BATTLE Trial as New Model for Biomarker-Based Drug Studies Premium Apr 1, 2011 Proteome Sciences Signs Contract with Takeda for Protein Biomarker Research Premium Feb 4, 2011 Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel Premium Feb 2, 2011 Eisai Invests in Development of Personalized Cancer Rx via Stake in Biotech Startup Premium Jan 31, 2011 Proteome Sciences Providing Biomarker Services to Eisai Jan 28, 2011 Eisai Creates US Subsidiary H3 Biomedicine with up to $200M Nov 18, 2010 Eisai Gains Access to Forma's Drug Screening Technology Load More Breaking News SARS-CoV-2 Variants of Concerns Evolved to Modify Host Immune Response, Multiomics Study Shows People in the News at GA4GH, Mercy BioAnalytics, Deepcell, One Biosciences New Products Posted to GenomeWeb: Clinical Microbiomics, Integra Biosciences, DNAstack, Bruker Angolan Namib Desert Population Analysis Uncovers New Ancestry Group With Deep Divergence Cedars-Sinai Sets Up $25M Single Cell Precision Medicine Center The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.